BioArctic announces additional BAN2401 Phase 2b study results in early Alzheimer’s disease presented by Eisai at the 2018 CTAD conference
Stockholm, Sweden, October 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical Phase 2b study with BAN2401 in 856 patients with early Alzheimer’s disease (AD). BAN2401 is a selective anti-amyloid beta (Aβ) protofibril antibody. Statistically significant benefits were observed on the key efficacy endpoints at 18 months on slowing progression in Alzheimer’s Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured by using amyloid-PET (Positron Emission Tomography)
